The in vitro activity of fusidic acid was assessed and was compared with those of cloxacillin, cefamandole, vancomycin, teicoplanin, ofloxacin, ciprofloxacin, pefloxacin, and fleroxacin against 500 gram-positive cocci: 151 Staphylococcus aureus, 197 coagulase-negative staphylococci, and 152 Enterococcus faecalis strains. All clinical isolates were concomitantly tested by disk diffusion and agar dilution procedures as outlined by the National Committee for Clinical Laboratory Standards. The results with fusidic acid were further analyzed by regression line and error rate-bounded methods. With control American Type Culture Collection organisms, the values were within the limits of the National Committee for Clinical Laboratory Standards or published limits. The incidence of resistance to fusidic acid was 0.7% for S. aureus, 2.5% for coagulase-negative staphylococci, and 99.3% for E. faecalis. The correlation coefficient between the results of disk diffusion and agar dilution tests with fusidic acid was 0.90. Current interpretive criteria for susceptibility to fusidic acid (i.e., MIC of <2 g/ml and inhibitory zone of >20 mm) gave 1% false susceptibility (all strains being E. faecalis). This error rate is practically eliminated if a zone diameter of >21 mm is considered the breakpoint for susceptibility.
Fusidic acid, a steroid-like antibiotic, has been in clinical use since 1962 (4) . Its antimicrobial activity and pharmacokinetics have been well documented (3, 5, 7, 12, 13, 15, 16) . However, there have been few recent studies of this antibiotic, despite renewed interest in its clinical application for the treatment of staphylococcal infections.
On the other hand, no National Committee for Clinical Laboratory Standards (NCCLS) criteria that can be used to interpret the results of susceptibility tests with fusidic acid are available because this antibiotic is not yet licensed for use in the United States. Current disk diffusion and agar dilution interpretive criteria are based on a study performed more than 20 years ago (14) .
The rising incidence and prevalence of beta-lactam-resistant staphylococcal infections and allergies to beta-lactam antibiotics are major factors involved in renewed interest in the use of fusidic acid (1, 3, 15) . Its clinical applications have increased significantly as an alternative to vancomycin in Europe, Asia, and Canada, and its approval in the United States is also possible (3, 15) .
This report describes (i) the in vitro activity of fusidic acid against gram-positive cocci in comparison with those of eight other antibiotics and (ii) the correlation between the results of disk diffusion and agar dilution tests with this agent. Current interpretive criteria are evaluated, and a slight modification is proposed.
(Results of this work were presented in part at the 89th Annual Meeting of the American Society for Microbiology New Orleans, La., 14 to 18 May 1989 [13a] .) Antimicrobial agents and test methods. Reference antibiotic powders and commercially available reference disks were kindly supplied by the antibiotics' manufacturers. Fusidic acid as 10-g disks, provided by Leo Laboratories Canada Ltd., Pickering, Ontario, Canada, were obtained from Oxoid (now Unipath), Nepean, Ontario, Canada. Mueller-Hinton culture medium was used for both disk diffusion and agar dilution tests. Antimicrobial susceptibility tests were performed in accordance with the procedures recommended by NCCLS (9, 10) .
MATERIALS AND METHODS
The concentrations of antimicrobial agents that inhibited 90% of strains tested (MIC 90 s) were calculated, and the percentage of resistant strains was evaluated with current NCCLS or other published interpretive breakpoints.
MICs and the diameters of the inhibition zones around the 10-g fusidic acid disks were compared by regression analysis by using the line equation Y ϭ mx ϩ b (where Y is log 2 nMIC, x is the zone diameter [in millimeters], m is the slope, and b is the y intercept). Inhibition zones of less than 6.5 mm and MICs of less than 0.06 g/ml or greater than 125 g/ml were excluded from analysis. Currently available interpretive criteria for fusidic acid were evaluated by the error rate-bounded method of Metzler and DeHaan (8) . Acceptable rates of error were Ͻ1% for false susceptibility and Ͻ5% for false resistance. The MIC breakpoint for resistance to fusidic acid was evaluated by the British Society for Antimicrobial Chemotherapy (BSAC) working party equation (17): MIC breakpoint ϭ (C max ϫ F:T ϫ E) ϫ S (where C max is peak concentration in blood, F is a factor for protein binding, T is a factor for half-life differences, E is the minimal C max :MIC ratio, and S is the shift for reproducibility).
RESULTS
The antibacterial activity of fusidic acid against ATCC control strains, as measured by disk diffusion and agar dilution tests, is presented in Table 1 . Zone diameters and MICs were within the limits published by other investigators (14) .
The in vitro activity of fusidic acid against the 500 clinical isolates of gram-positive cocci is provided in Table 2 . The species of the coagulase-negative staphylococci tested were determined. The inhibition zone diameter range, MIC range, MIC 50 s, and MIC 90 s are documented for the whole group of organisms and for each species if more than 10 isolates of each species were tested. Our results confirm old and rather new reports which described the remarkable antibacterial activity of fusidic acid against gram-positive cocci, regardless of their susceptibilities to other agents (1-6, 11, 15) . Table 3 reports the incidence of resistant strains and the comparative in vitro activities of fusidic acid and eight other antibiotics against 500 gram-positive cocci. No matter what MIC breakpoint was chosen for resistance to fusidic acid (i.e., Ն2 or Ն4 g/ml), the incidence of resistant staphylococcal strains was very low. We should mention that among the S. aureus strains in our series, only 4% were resistant to cloxacillin. Their susceptibility to fusidic acid was quite similar to that of cloxacillin-susceptible strains. However, the only S. aureus strain resistant to fusidic acid in the present study was also resistant to cloxacillin.
Virtually all of the enterococci tested were resistant to fusidic acid, while all of them were susceptible to teicoplanin and ofloxacin. A low level of resistance (1.8%) was encountered with vancomycin.
Regression lines for comparative testing of fusidic acid against the 500 clinical isolates of gram-positive cocci are provided in Fig. 1 . A correlation coefficient of 0.90 was found between the results of disk diffusion and agar dilution procedures. The y intercept and the slope of the regression line for 10-g fusidic acid disks were 7.455 and Ϫ0.348, respectively.
The MIC breakpoint for resistance to fusidic acid was assessed with the formula recommended by the BSAC working party, where the breakpoint MIC ϭ (C max ϫ F:T ϫ E) ϫ S. We assumed the following values on the basis of published phar- a CNS, coagulase-negative staphylococci. b S. warneri (n ϭ 8), S. capitis (n ϭ 3), S. saprophyticus (n ϭ 3), S. simulans (n ϭ 2), S. cohnii (n ϭ 2), and S. sciuri (n ϭ 1). . By using this formula, an MIC breakpoint of 3 g/ml is consistent with available pharmacokinetic data. By the error rate-bounded analysis with two possible MIC equivalents for resistance (Ն2 g/ml or, better, Ն4 g/ml) and the current zone diameter of Ն20 mm for susceptibility, the rates for false susceptibility and false resistance to fusidic acid were 1 and 0.2%, respectively.
To reduce the rate of false susceptibility to fusidic acid, a change of the inhibition zone diameter from Ն20 to Ն21 mm is proposed.
MICs for resistance to fusidic acid of both Ն2 and Ն4 g/ml seem appropriate. However, an MIC of Ն4 g/ml appears to be more useful in practice because it takes into consideration the provision for intermediate susceptibility, the concordance with the BSAC working party formula, and it is only the next higher drug concentration to Ն2 g/ml in a binary dilution procedure.
The proposed interpretive criteria for the susceptibility testing of gram-positive cocci to fusidic acid are as follows: for categories of susceptible, intermediate, and resistant, MICs of Ͻ2, Ն2 to Ͻ4, and Ն4 g/ml, respectively, and inhibition zone diameters of Ն21, Ͻ21 to Ͼ19, and Յ19 mm, respectively. These very slightly modified endpoints allow a reduction of false susceptibility to zero and define an intermediate susceptibility category.
DISCUSSION
The main goals of the present work were to assess the antibacterial activity of fusidic acid against gram-positive cocci, to analyze the correlation between the results of disk diffusion and agar dilution tests, and to propose more appropriate interpretive criteria for susceptibility testing of gram-positive cocci to fusidic acid.
The present study confirmed the high antistaphylococcal activity of fusidic acid, despite more than 30 years of clinical use in many parts of the world (2-6, 11, 15).
The incidence of resistance of S. aureus was only 0.7% when most of this work was done and when the level of resistance to cloxacillin was only 4%. Four years later, at the same institution, the incidence of methicillin-resistant S. aureus was 11% and the resistance to fusidic acid was 4% when an MIC of Ն2 g/ml for resistance was used [11a] ). Half of the S. aureus strains resistant to fusidic acid were also methicillin resistant.
Against coagulase-negative staphylococci, including 27.9% cloxacillin-resistant strains, fusidic acid displayed very good activity, with only 2.5 or 1% resistance according to the MIC (Ն2 or Ն4 g/ml, respectively) chosen as the breakpoint for resistance. Its antistaphylococcal activity compared well with those of other antibiotics such as the new fluoroquinolones, vancomycin, and teicoplanin.
The incidence of resistant strains and the in vitro activities of fusidic acid and the other eight antibiotics against our clinical isolates were comparable to published data when most of the present work was done (2-6, 11). We should emphasize that at that particular time, ciprofloxacin was the only approved fluoroquinolone among those tested at our hospital and that teicoplanin was used only in a few patients enrolled in a clinical trial.
Available pharmacokinetic data on fusidic acid indicate that usual oral doses in humans yield levels in serum which greatly surpass the MIC breakpoint for resistance, despite the highlevel protein-binding characteristics of this antimicrobial agent (7, 12, 13, 16) .
A resurgence in the incidence of infections caused by grampositive cocci and increased clinical use of vancomycin have been reported by several centers in both Europe and North America (1, 3, 15) . Consequently, as expected, resistance to vancomycin has become a reality, especially for enterococci. The potential for an elevated incidence and occurrence of staphylococcal infections should not be underestimated. Furthermore, vancomycin is associated with a high incidence of nephrotoxicity and other adverse reactions, making monitoring of levels in serum virtually mandatory. Alternatives to vancomycin are therefore necessary, and fusidic acid appears to be a good choice. It warrants consideration for use in the treatment of infections caused by gram-positive cocci resistant to betalactam antibiotics or in individuals allergic to beta-lactam antibiotics.
At this time, there are no interpretive criteria approved by NCCLS for the susceptibility testing of gram-positive cocci to fusidic acid, because this antibiotic is not currently licensed for use in the United States. Present guidelines in countries where fusidic acid has been approved for clinical use were determined many years ago and on a reduced number of bacterial isolates (14) . Our data showed that current guidelines are appropriate when testing staphylococci but that a high incidence of false susceptibility may be encountered, especially with enterococci.
Although fusidic acid is not indicated for treating or even testing enterococci, it could be included in the group of antibiotics designated for evaluating the susceptibilities of grampositive cocci. This might lead to misinterpretation or erroneous clinical use against enterococcal infections.
Error rate-bounded analysis minimizes interpretive errors (8) . By using this method and changing the zone diameter breakpoint for susceptibility to Ն21 mm instead of Ն20 mm, the error rate for false susceptibility (or a major error) is nil.
The MIC breakpoint for resistance should probably be Ն4 g/ml rather than Ն2 g/ml. The choice of this breakpoint is justified by pharmacokinetic data and the BSAC working party formula. It did not change the rates of false susceptibility or false resistance to fusidic acid. Moreover, in addition to the proposed disk diffusion criterion for susceptibility, it allows provisions for the category of intermediate susceptibility.
In conclusion, fusidic acid is a very active antistaphylococcal agent, despite more than 32 years of clinical use. It should be considered an alternative to vancomycin for the treatment of staphylococcal infections. The present interpretive criteria for susceptibility testing of this antibiotic could advantageously be changed to those that we have proposed here. However, further new pharmacokinetic data, in vitro activity studies, and assessment of the proposed interpretive guidelines are needed.
